Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1947 results
July 2026
-
Press release
FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease
Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient populationPSMAddition updated results show Pluvicto reduced risk of progression or death by 33% in… -
Story Discovery
Smarter decisions at scale: How Novartis is using AI to advance R&D
Novartis R&D is harnessing digital technologies to make smart decisions faster, aiming to reduce the time it takes to bring new options to patients
-
Story People and Culture
Small shifts. Big impact. The leadership choices that matter most in the age of AI
There is no shortage of conversation about what AI can do. Every day brings a new headline, a new capability, a new prediction about how work will change.
-
Story Discovery
How Novartis R&D is advancing the next breakthrough innovations
Novartis R&D leaders discuss how Novartis science, technology and strategy are shaping the next decade of innovation
-
Ad hoc release
Novartis verzeichnete im zweiten Quartal Umsatzsteigerungen und baute die Pipeline weiter aus; Prognose für das Geschäftsjahr bekräftigt
Ad-hoc-Mitteilung gemäss Art. 53 KRZweites QuartalDer Nettoumsatz stieg um +1% (kWk1, +3% USD), das operative Kernergebnis1 blieb unverändert (kWk und USD)Das Umsatzwachstum beruhte auf den… -
Ad hoc release
Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed
Ad hoc announcement pursuant to Art. 53 LRSecond quarterNet sales grew +1% (cc1, +3% USD), with core operating income1 flat (cc and USD)Sales growth driven by priority brands including Kisqali (+43%… -
Story People and Culture
Novartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next
The roots of Novartis reach back more than 250 years, to the chemical and scientific traditions that helped shape modern healthcare. Thirty years after its creation, a legacy of discovery and curiosity continues to guide its pursuit of new possibilities for patients.
-
Press release
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of protein in urine observed as early as two weeks,… -
Press release
Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients
Adds potential first-in-class, N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform, designed to address resistance to current payloads Strengthens the Novartis… -
Press release
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
First gene replacement therapy in the EU for broad population with SMA, including children two years and older, teens and adults Fixed, one-time dose designed to replace the faulty SMN1 gene,…